PMID- 11714594
OWN - NLM
STAT- MEDLINE
DCOM- 20020104
LR  - 20190906
IS  - 0376-8716 (Print)
IS  - 0376-8716 (Linking)
VI  - 65
IP  - 1
DP  - 2001 Dec 1
TI  - The subjective effects of MDMA and mCPP in moderate MDMA users.
PG  - 97-101
AB  - The present study is part of a research program designed to better understand the 
      neurochemical mechanisms underlying the abuse liability of 
      3,4-methylenedioxymethamphetamine (MDMA) in humans. In these studies, MDMA will 
      be compared to prototypical dopamine (D-amphetamine) and serotonin 
      (meta-chlorophenylpiperazine, mCPP) releasing agents on a variety of measures 
      related to dependence. In order to determine an acceptable dose range (safe but 
      active) of MDMA and mCPP for these studies, moderate MDMA users were administered 
      escalating doses of MDMA (75, 110 and 145 mg/70 kg) and mCPP (17.5, 35 and 52.5 
      mg/70 kg). Each participant received a single dose under controlled laboratory 
      conditions, i.e. this was a six-group design with a separate group for each dose. 
      There were five participants tested in each group. MDMA increased blood pressure 
      and heart rate whereas mCPP had no effect on these physiological measures. MDMA 
      produced increases in subjective effects indicative of both stimulant (increases 
      in POMS Elation, ARCI Amphetamine, VAS High and Stimulated scale scores) and 
      hallucinogenic effects (increases on five of the six scales of the Hallucinogenic 
      Rating Scale). mCPP produced similar stimulant effects (e.g. increases on POMS 
      Elation, VAS High and Stimulated), as well as hallucinogenic effects (four of the 
      six scales of the Hallucinogenic Rating Scale), which has not been observed in 
      previous studies.
FAU - Tancer, M E
AU  - Tancer ME
AD  - Substance Abuse Research Division, Department of Psychiatry and Behavioral 
      Neurosciences, Wayne State University School of Medicine, Detroit, MI 48207, USA. 
      mtancer@med.wayne.edu
FAU - Johanson, C E
AU  - Johanson CE
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Ireland
TA  - Drug Alcohol Depend
JT  - Drug and alcohol dependence
JID - 7513587
RN  - 0 (Hallucinogens)
RN  - 0 (Piperazines)
RN  - 0 (Serotonin Receptor Agonists)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - REY0CNO998 (1-(3-chlorophenyl)piperazine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Affect/*drug effects/physiology
MH  - Analysis of Variance
MH  - Blood Pressure/drug effects/physiology
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Hallucinogens/*administration & dosage
MH  - Heart Rate/drug effects/physiology
MH  - Humans
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*administration & dosage
MH  - Piperazines/*administration & dosage
MH  - Serotonin Receptor Agonists/*administration & dosage
MH  - Substance-Related Disorders/*psychology
EDAT- 2001/11/21 10:00
MHDA- 2002/01/10 10:01
CRDT- 2001/11/21 10:00
PHST- 2001/11/21 10:00 [pubmed]
PHST- 2002/01/10 10:01 [medline]
PHST- 2001/11/21 10:00 [entrez]
AID - S0376-8716(01)00146-6 [pii]
AID - 10.1016/s0376-8716(01)00146-6 [doi]
PST - ppublish
SO  - Drug Alcohol Depend. 2001 Dec 1;65(1):97-101. doi: 10.1016/s0376-8716(01)00146-6.